Cancer type | Sample type | Expression pattern | Gene interplay (Direct or Indirect) | Signaling pathways | Reference | |
---|---|---|---|---|---|---|
Cell line | Patients | |||||
Hepatocellular carcinoma | HepG2 and SMMC-7721Â | HCC tumor tissue | Down-regulated | Hes-1, NICD, E-cadherin, and Claudin-1 | Notch and EMT signal pathways | [6] |
Prostate cancer | LNCaP, DU145, PC3, PTN2 and BPH-1 | Prostatectomy specimens | Down-regulated | p53, Mdm2, Puma, Noxa and Bax | P53 Signaling | [7] |
Head and neck squamous cell carcinoma | HN4, HN6, HN30 HEK293T, Cal27, SCC25, Detroit562, MCF7, and MDA-MB-231 | HNSCC tumor tissues | Down-regulated | p53 and NF-YA | JAK2/STAT3 signaling | [9] |
Skin cancer | Balb/MK2 keratinocytes, NHEKs | – | Down-regulated | P53 | p53 pathway | [10] |
Gastric cancer | MGC-803, MKN-45, BGC-823, MKN-28, SGC-7901 and normal GES-1 | GC tissues | Down-regulated | imentin and N-cadherin, YAP, β-catenin and NF-κB, P-ERK | Hippo pathway | [12] |
Chronic lymphocytic leukemia | LY-47, BL-60 and BL-7, BJAB, BL-2, and CA-46Â | PBMC from patients | Up-regulated after DNA damage | P53, p21 | p53 pathway | [13] |
Non-small cell lung cancer | H23, H1299, and HCC-44 | NSCL tumor tissue | Down-regulated | Secreted vascular endothelial growth factor A (VEGFA) | – | [14] |
Colorectal cancer | CRC cell lines HCT-116 (p53þ/þ) and HCT-116 (p53−/−) | CRC specimens | Down-regulated | P53 | – | [15] |
B cell lymphoma | – | DLBCL tissues | Down-regulated | Cyclin D1, CDK4 and p21 | – | [16] |